Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.01.04.22268717: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The project was approved by the Institutional Review Boards at Qatar University (QU-IRB 1492-E/21 and QU-IRB 1469-E/21). Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study had some limitations; most of our RT-PCR samples were collected from asymptomatic individuals (Table S1), which might have …
SciScore for 10.1101/2022.01.04.22268717: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The project was approved by the Institutional Review Boards at Qatar University (QU-IRB 1492-E/21 and QU-IRB 1469-E/21). Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study had some limitations; most of our RT-PCR samples were collected from asymptomatic individuals (Table S1), which might have underestimated the assay’s sensitivity. In addition, the control group did not include samples for other coronaviruses or influenza that might cross-react with SARS-CoV-2, which could have led to an overestimated specificity. In conclusion, our data showed that FineCare™ 2019-RBD antibody test demonstrated excellent performance in terms of sensitivity, specificity, and overall agreement with RT-PCR as a reference test. In addition, correlation with the FDA-approved sVNT from Genscript and the automated analyzer VIDAS®3 from bioMérieux, FineCare™ immunoassay showed an outstanding performance in detecting total antibodies in serum samples against SARS-CoV-2. Thus, this assay could be reliable for the quantitative detection of antibodies in the vaccinated population and recovered patients.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
